Clinical trial · Observational
Distribution and Prognostic Impact of Oncogenic Drivers in Metastatic Lung Adenocarcinoma : a Retrospective Monocentric Study in Nancy University Hospital Center
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The recent discovery of oncogenic drivers has revolutionized the management of advanced lung cancer by development of tyrosine kinase inhibitors targeted therapies. Prevalence of daily tobacco use is evaluated at 31,3 % in Grand-Est region, the only French region with a statistically significative difference for smoking habits. This region shows a higher incidence (+ 13 %) and mortality for lung cancer in comparison to the average for other French regions. The objectives of our studie were to estimate the distribution of oncogenic drivers and analyse their prognostic impacts in the Nancy University Hospital Center metastatic lung adenocarcinoma's population.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Adenocarcinoma of Lung, Response to Tyrosine Kinase Inhibitor in, Somatic | Lung Adenocarcinoma | ALIAS | 0.85 |
| Adenocarcinoma of Lung Stage IV | Lung Adenocarcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (3)
- measure
- Overall survival
- timeFrame
- over a period of 5 years (Day 0 = anatomopathological diagnosis)
- description
- Time (in months) from anatomopathological diagnosis to death
- measure
- Progression Free survival
- timeFrame
- over a period of 5 years (Day 0 = anatomopathological diagnosis)
- description
- Time (in months) from anatomopathological diagnosis to progression of the disease assessed by RECIST criteria
- measure
- Distribution in percentage of main oncogenic drivers in histological samples from metastatic lung adenocarcinoma
- timeFrame
- At base line (Day 0 = anatomopathological diagnosis)
- description
- Distribution in percentage of main oncogenic drivers (KRAS, EGFR, ALK, ROS-1, BRAS and HER2), assessed by Sanger sequencing or FISH method in histological samples from metastatic lung adenocarcinomas
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Lung adenocarcinoma * Patients diagnosed at a metastatic stage * Patient who benefited an oncogenic driver research on their histologic samples * Medical follow-up entirely done in Nancy Central Hospital Exclusion Criteria: * Patients with double histology * Synchronous cancer * Patients with surgical care
References
Publications (0)
Data not yet available